NASDAQ:MGNX • US5560991094
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MACROGENICS INC (MGNX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-10 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-03 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-08-15 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-05-20 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2025-05-14 | Stifel | Maintains | Hold -> Hold |
| 2025-05-14 | Barclays | Maintains | Overweight -> Overweight |
| 2025-03-25 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-11-07 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-09-18 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-21 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-15 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-07 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-08-01 | BTIG | Downgrade | Buy -> Neutral |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-07-31 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-07-31 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-31 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2024-07-31 | Barclays | Maintains | Overweight -> Overweight |
| 2024-07-29 | Barclays | Maintains | Overweight -> Overweight |
| 2024-05-24 | BTIG | Maintains | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-05-10 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-05-10 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2024-05-10 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 58.749M -61.32% | 149.962M 155.26% | 149.5M -0.31% | 62.883M -57.94% | 73.032M 16.14% | 115.79M 58.55% | 85.33M -26.31% | 135.51M 58.81% | 212.55M 56.85% | 365.93M 72.16% | 516.86M 41.25% | |
| EBITDA YoY % growth | -158.599M -44.80% | -103.038M 35.03% | -65.669M 36.27% | -128.52M -95.71% | -126.48M 1.59% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -168.244M -38.59% | -110.578M 34.28% | -72.841M 34.13% | -125.12M -71.77% | -125.679M -0.45% | -159.836M -27.18% | -222.54M -39.23% | -180.728M 18.79% | -105.248M 41.76% | 28.521M 127.10% | 130.21M 356.54% | |
| Operating Margin | -286.38% | -73.74% | -48.72% | -198.97% | -172.09% | -138.04% | -260.80% | -133.37% | -49.52% | 7.79% | 25.19% | |
| EPS YoY % growth | -1.77 8.76% | -1.08 38.98% | -1.18 -9.26% | -1.95 -65.10% | -1.85 5.24% | -1.51 18.23% | -1.38 8.78% | -1.21 11.85% | -1.05 13.45% | 0.22 121.36% | 1.44 540.91% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.54 16.60% | -0.61 -7.31% | -0.53 -298.08% | -0.48 -106.81% |
| Revenue Q2Q % growth | 15.946M 20.88% | 9.078M -59.18% | 9.078M -87.54% | 9.078M -77.98% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -30.967M 27.35% | -44.166M -20.15% | -44.166M -336.99% | -45.9M -279.43% |
All data in USD
13 analysts have analysed MGNX and the average price target is 3.47 USD. This implies a price increase of 18.36% is expected in the next year compared to the current price of 2.93.
MACROGENICS INC (MGNX) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of MACROGENICS INC (MGNX) is -0.54 USD and the consensus revenue estimate is 15.95M USD.
The number of analysts covering MACROGENICS INC (MGNX) is 13.